Finland· FI-REL-REL60913

Omjjara

A momelotinib product containing momelotinib dihydrochloride monohydrate, registered in Finland by Glaxosmithkline Trading Services Limited. The same ATC class is registered in 15 of our 19 countries.

ATC L01EJ04

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedOmjjaraATCL01EJ04REGISTER NO.FI-REL-REL60913PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Momelotinib is registered in 15 of 19 countries.

Countries holding a registration under ATC L01EJ04 (momelotinib), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose

Momelotinib · ATC L01EJ04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of momelotinib costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $309.44 in Switzerland — a ×1929 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Momelotinib · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$309.44
  • FR France$0.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Momelotinib dihydrochloride monohydrate
Manufacturer
Glaxosmithkline Trading Services Limited
Country
Finland (FI)
ATC code
L01EJ04
ATC class
Momelotinib
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f736b1fc-5dfb-4185-8b55-acfd9027bd7e
GET /v1/drugs/f736b1fc-5dfb-4185-8b55-acfd9027bd7e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.2",
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": "g",
  "strength": "100 mg",
  "atc_label": "momelotinibi",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/23/1782/001",
  "fimea_rel_id": "REL60913",
  "authorised_at": "2024-01-25"
}

See everything about momelotinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.